In conclusion, the regimen with fulvestrant in combination with oral vinorelbine was efficacious, tolerable, and convenient to use in patients with HR+/HER2− advanced breast cancer and hence may be considered in clinical practice. The gene discussed is HR; the disease is breast cancer.